We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » DRUGMAKERS NOT SWAYED BY ADA RISK STUDY ON ANTIPSYCHOTICS
DRUGMAKERS NOT SWAYED BY ADA RISK STUDY ON ANTIPSYCHOTICS
January 28, 2004
Despite a statement from four prominent medical associations warning about the risk of adverse side effects of some antipsychotics, Pfizer continues to resist FDA-requested labeling changes for its Geodon (ziprasidone HCl) product.